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Background: Radiotherapy is controversially discussed in the management of benign disorders for fear of late
sequelae such as tumor induction. This study was initiated to investigate long-term toxicity, treatment outcome
and prognostic factors after radiotherapy (RT) in patients with pituitary adenomas.
Methods: 92 patients with pituitary adenomas were included in this analysis. RT was conducted using either 3D
conformal (16%) or fractionated stereotactic techniques (83%) in a postoperative adjuvant setting (16%), as
second-line treatment for recurring tumors (78%) or as primary treatment (6%). Postoperatively, RT was offered to
patients with residual tumor tissue or in case of locally extensive adenomas, in whom early recurrence was deemed
likely. Patients were followed for a median time of 152.5 months, and analysed for overall and local progression-free
survival (OS and LPFS). Multiple factors were analysed for prognostic impact. Patients were contacted with an
institutional questionnaire about qualiy of life (QOL). Statistical analysis was performed using the log-rank test and
the Kaplan-Meier method using a software tool (SPSS 19.0).
Results: Median follow-up was 152.5 months. Before treatment, 2% of all patients were diagnosed with
adenoma-related hypopituitarism. Following surgery, 68% suffered from new pituitary deficits. RT was associated
with mild toxicity, including visual deficits (5.4%) and hypopituitarism (10.9%). In particular, no radiation-induced
brain necrosis or malignancy was observed. QOL was reported to be stable or improved in 92% of all patients, and
RT was perceived to not compromise but increase QOL in the vast majority of patients (95%). OS after RT was
93.3% and 61.0% at 120 and 240 months. LPFS following RT was 90.4 and 75.5% at 120 and 240 months. Early
initiation of RT after surgery instead of reserving it for recurring adenomas predisposed for improved outcome.
Conclusions: RT for pituitary adenomas is safe and and self-reported QOL is stable or improved by almost all
patients. Hypopituitarism rates are low. Local control appears improved in patients irradiated postoperatively over
those undergoing RT for previously resected recurrent tumors.
Keywords: Pituitary, Adenoma, Secreting, Stereotactic, Endocrine, Toxicity* Correspondence: Stefan.Rieken@med.uni-heidelberg.de
1Department of Radiation Oncology, University Hospital of Heidelberg, Im
Neuenheimer Feld 400, 69120 Heidelberg, Germany
2Neuro-Radiation Oncology Research Group, Department of Radiation
Oncology, University of Heidelberg, Im Neuenheimer Feld 400, 69120
Heidelberg, Germany
© 2013 Rieken et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Rieken et al. Radiation Oncology 2013, 8:18 Page 2 of 7
http://www.ro-journal.com/content/8/1/18Introduction
Pituitary adenomas are benign tumors representing 10 –
15% of primary intracranial tumors. Depending upon their
histopathology, they are inactive or hormone-secreting
lesions [1,2]. They are frequent causes of pituitary dys-
function comprising both suppression-related hypopituit-
arism, but also adenoma-derived hypersecretion [3].
Besides endocrinological morbidity, pituitary adenomas
often lead to visual impairment related to both optic nerve
affection with reduced visual fields and acuity, but also
disturbed oculomotor function – especially in cases of
cavernous sinus infiltration [4]. It has been discussed con-
troversially whether RT should be delivered after surgery,
which is regarded as the preferential initial treatment.
Additionally, substantial discussion has focussed on which
risk factors can be identified arguing for early adjuvant
treatment [4-6].
In general, indication for RT is set for recurrent
tumors, for atypical histology, or for persistent hormone
secretion. Cranial RT for pituitary adenomas, but also
for target volumes in close proximity to the sella has re-
peatedly been reported to be a cause of hypopituitarism
[7-9]. Varying intervals between RT and decline in hor-
mone levels have been published, ranging from one to
more than ten years [10,11]. Also, distinct threshold
doses for the various hormone-secreting cells have been
described, resulting in characteristic clinical courses,
commonly starting with loss of growth hormone [9].
Taking further potential sequelae such as visual deficits
[12], cerebral radiation injury [13] and tumor induction
[1,14] into consideration, the role of RT for benign
lesions of the pituitary gland has repeatedly been chal-
lenged. Moreover, controversial data on when to irradi-
ate (primary vs. postoperative vs. salvage), whom to
irradiate (secreting vs. non-secreting) and how to irradi-
ate (fractionated stereotactic RT vs. radiosurgery vs.
intensity modulated RT) have occupied scientists, clini-
cians and patients [5,15-17]. Several authors have
addressed short- and medium-term outcome in irra-
diated pituitary adenoma patients [18,19], however little
data is available on long results and toxicity.
We previously analysed short-term outcome with con-
ventional RT and fractionated stereotactic RT for pituitary
adenomas [2,20,21]. In the present report, we summarized
our long-term experiences in the management of pituitary
adenomas after a follow-up of more than 10 years in 92
patients.
Patients and methods
Between 1984 and 2010, 92 patients with pituitary aden-
omas were treated at the University hospital in Heidelberg,
Germany. All data were collected retrospectively and in
accordance with institutional ethical policies. Additionally,
patients were contacted to update their charts on currenthormone replacement medication, QOL and potential
additional therapies. Median follow-up time since first
diagnosis was 152.5 months (range 9 – 548 months) and
99 months (range 1 – 310 months) since RT.
Patient characteristics
Patient characteristics are summarized in Table 1.
In 31 patients, endocrine symptoms were present at
first diagnosis, including 29 patients with signs of hyper-
secretion and 2 with suppression of pituitary function.
Impairment of the optic nerve was present in 28 patients
(30%) at first diagnosis, while disturbed oculomotor
function was diagnosed in 6 patients (7%).
Surgery and histopathological findings
Surgery was chosen as first treatment in 87 patients (95%).
Only 5 patients with inoperable macroadenomas under-
went primary RT. Extent of surgery was assessed by the
surgeon. Surgery was deemed complete in 35 patients
(40% of 87). Macroscopic tumor residues were described
in 52 patients (60% of 87). In recurrent patients, re-
surgery was performed in 48 patients (55% of 87) and was
complete in 8 patients (17% of 48). Histological and blood
hormone analysis identified 37 patients with secreting
adenomas (40%), including 22 somatotropinomas (59%), 8
prolactinomas (2%), 6 corticotropinomas (16%), and one
thyrotropinoma (3%). Non-functioning adenomas were
diagnosed in 55 patients (60%).
Radiotherapy
RT was carried out as fractionated stereotactitc irradi-
ation in the majority of patients (n = 76, 83%). Before
introduction of stereotactic methods in the mid 1990s,
15 patients were treated with 3D conformal techniques
(16%). For reason of extensive cavernous sinus infiltra-
tion, 1 patient (1%) was treated with an IMRT treatment
plan. Treatment was planned based upon CT and MRI
images. Target volumes encompassed any visible tumor
adding a safety margin of 2 to 3 millimeters. Median
planning target volume was 25.6 milliliters. Median total
dose was 52.2 Gy with median single doses of 1.8 Gy.
Follow-up
Patients were seen 8 weeks after completion of irraditia-
tion and yearly hereafter. We recommended testing of
both visual acuity and field and blood chemistry analysis
of hormonal state 6 and 12 months following RT. Most
patients were monitored annually by their treating physi-
cians. Hypopituitarism was defined as requirement for
new hormonal replacement therapy. Imaging diagnosis
was perfomred using MRI in all patients since the mid-
90s. It was routinely included in the pretreatment plan-
ning procedure and additionally performed during
follow-up with no fixed intervals, but at the discretion of
Table 1 Summary of patient characteristics
Patient characteristics
biometric (years) (range)








pituitary subfunction 2 2
hormonal excess 29 32

























median single dose 1.8 1.8 – 2.0
median total dose 52.2 48.6 – 58.0
(n) (%)
primary definitive RT 5 5
postoperative RT 15 16
RT for recurrent tumors 72 78
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diagnosed in case of new diagnosed tumor formation in
cross sectional imaging or in case of re-increasing hormone
levels. During this analysis, patients were recently contacted
for updated information on present hormone replacement
treatment. Also, they were asked about alterations ofgeneral QOL following initial diagnosis and treatment and
whether or not QOL was changed by RT.
Statistical analysis
OS was calculated from the date of primary diagnosis
until the last date of follow-up or death. LPFS since first
diagnosis and LPFS since RT were calculated in months
from the date of initial diagnosis until the first imaging
or serological-endocrine diagnosis of tumor relapse and
from the date of the first RT fraction until the first
imaging or serological-endocrine diagnosis of tumor
relapse, respectively. Results were displayed with the
Kaplan-Meier method. Survival curves were compared




RT was conducted without interruptions ≥ 4 days in all
patients. No severe early or late treatment-related side
effects were observed, including cerebral hemorrhages
or brain necroses. At the time of initial diagnosis and
prior to RT and surgery, 29 patients (31.5%) presented
with low visual acuity or visual field deficits (31.5%).
After surgical intervention, 14 new visual impairments
were reported (16.1%). Of all patients at risk of visual
side effects due to prior impairment, 5 patients com-
plained about new symptoms following RT (5.4%),
mostly comprising limited visual field deficits. There was
no complete amaurosis following RT. There were no
secondary malignancies. Five patients suffered from can-
cer during follow-up, however, none of them related to
cranial RT fields (2 × prostate, 1 × gastric, 1 × lung, 1 ×
breast cancer).
Up-front tumor-related hypopituitarism was diagnosed
in 2 patients (2.2%). Following surgical resection, 59 of 87
patients developed new pituitary deficit (68%). RT caused
new deficits in 10 patients (10.9%), including thyreotrope
(50%), somatotrope (40%), corticotrope (60%), and gona-
dotrope (20%) imbalances. All patients had received sur-
gery prior to RT, and had also received partial hormone
replacement therapy for postoperative deficits, indicative
of preexisting postoperative damage of the pituitary gland.
In reverse, no patient undergoing primary definitive RT
for pituitary adenoma developed a new pituitary deficit.
At the time of data collection, 71 patients were on hor-
mone replacement therapy including mineralocorticotrope
(80.6%), thyroxine (n = 52; 73.2%), testosterone (n = 46,
64.8%) and somatotrope (n = 16; 22.5%) substitution.
Chronic administration of vasopressin was necessary in 5
patients (5.4%).
Patients reported high QOL following initial diagnosis
and treatment with 24% stating improved and 68% stat-
ing stable QOL. Only 7% reported reduced QOL due to
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anced hormonal replacement in two thirds. RT was
reported to have improved or not affected QOL in 95%
of all patients (17% and 78%). Reduction in QOL due to
chronic toxicity was perceived by only 5%.Figure 2 OS in 92 patients with pituitary adenomas after RT.Survival and prognostic factors
Median follow-up since the initial diagnosis of adenoma
was 152.5 months (range 9 – 548 months). Most patients
underwent RT for recurrent disease, therefore causing a
median latency of 39 months between initial diagnosis and
initiation of RT (range 1 – 404 months). After RT, median
follow-up was 99 months (range 1 – 310 months).
OS since first diagnosis was 98.9%, 97.4%, 87.2% and
70.2% at 12, 120, 240, and 360 months (Figure 1). OS after
RT was 96.6%, 93.3%, 61.0%, and 61.0% at 12, 120, 240,
and 360 months (Figure 2). Extent of surgery did not in-
fluence OS since initial diagnosis or since RT (p = ns).
Concerning endocrinological characteristics, OS was not
influenced by hormone secretion (yes vs. no, p = 0.421). OS
after 5, 10 and 20 years was 100, 96, and 81% in patients
with functioning adenomas and 98, 98 and 90% in those
with non-functioning adenomas. Patients with functioning
adenomas had 5-, 10-, and 20-year LPFS rates of 87%, 81%,
and 81% as opposed to 100, 100, and 74% in non-
functioning adenomas. OS and LPFS were not affected by
postoperative oor radiogenic hormonal deficits (yes vs. no;
p = 0.445 and p = 0.863). Also, the need of hormone substi-
tution therapy following treatment did not impair OS rates
(p = 0.836). Of 92 patients, 31 were initially diagnosed with
pituitary adenomas for reason of endocrine symptoms,Figure 1 OS in 92 patients with pituitary adenomas after initial
diagnosis.including hypersecretion (n = 29) and tumor-related hypo-
pituitarism (n = 2).
Most patients underwent RT for recurrent pituitary
adenoma. Surgery for newly diagnosed pituitary tumor
was chosen in 87 patients (94.6%). In this highly selected
cohort with recurrent and locally advanced patients,
LPFS since initial diagnosis and primary surgery was
80.9, 37.8, 25.3, and 9.2% after 12, 60, 120, and 240
months (Figure 3). It was not improved by complete vs.
incomplete resection (p = 0.891). LPFS since RT was
100.0, 92.5, 90.4, and 75.5% after 12, 60, 120, and 240Figure 3 LPFS in 92 patients with pituitary adenomas after
initial surgery.
Figure 5 LPFS in 87 patients treated with pituitary RT either
postoperatively (blue line) or for relapsing adenomas
(green line). There is a strong trend towards improved local control
in patients undergoing postoperative RT (p = 0.098/ns).
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enced by hormone secretion (secreting vs. non-secreting;
p = 0.294), sex (male vs. female; p = 0.71), surgery (yes vs.
no; p = 0.75), extent of resection (complete vs. incom-
plete; p = 0.45).
We observed a trend towards improved LPFS in those
patients who received RT in a postoperative or primary
setting instead of reserving it for patients with recurrent
disease (p = 0.098/ns; Figure 5). There was no relapse in
patients with primary or postoperative RT, whereas local
control in patients treated for local recurrence was
100.0, 90.8, 88.2, and 62.0% after 12, 60, 120, and 240
months. Due to the small number of patients treated
early after diagnosis (n = 18), statistical significance was
not, yet, reached (p = 0.098).
Patterns of relapse
Seven patients suffered from relapse after RT (7.6%).
Median latency between RT and relapse was 36 months
(range 27 – 156 months). Recurring adenomas were se-
creting in 4 patients (57.1%) and non-secreting in 3
patients (42.9%). In 5 patients, morphological tumor
mass was present and detected through cross-sectional
imaging, while in 2 patients with growth hormone se-
creting tumors, relapse was diagnosed based on blood
hormone analysis with no macroscopic tumor tissue vis-
ible. Salvage treatments comprised reirradiation in 2
patients, resurgery in 3 patients, and sole pharmaco-
logical therapy in 2 patients.
There was no relapse in the 5 patients who received
sole RT without prior surgical intervention. Also, no re-
currence was diagnosed in patients undergoing surgery
followed by early postoperative RT.Figure 4 LPFS in 92 patients with pituitary adenomas after RT.Discussion
In the present manuscript, we analysed treatment out-
come and toxicity in 92 patients with pituitary aden-
omas: We found RT to be safe and associated with little
toxicity in primary, adjuvant and second-line line treat-
ment regimes. Local control of disease was high with
long patient survival. RT as a postoperative treatment
option during first-line treatment appeared superior to
reserving it for relapsing patients.
Previouly, our group had reported short-term outcome
after conventional RT treated from 1972 to 1991 with
promising outcome [21]. With the advent of high-precision
techniques, these were implemented for benign lesions, and
early outcome for secreting and non-secreting pituitary ad-
enomas has been evaluated [2,20]. For benign lesions, how-
ever, long-term local control, QOL and chronic side effects
are of utmost importance for the assessment of efficacy.
Therefore, the present analysis has set one focus on
these issues. Improved QOL was reported by 24% and
stabilization of QOL was noted by 68% of all patients.
Despite well-known risks for critical visual and endocrine
functions, RT was reported to have exerted negative impact
on QOL in only 5%, while 95% of all patients assessed RT
to have secured or enhanced their QOL. Acute and chronic
toxicity was very moderate in the current patient cohort,
and no treatment-interrupting sequelae occurred. One
third of all patients had visual deficits at the time of the ini-
tial diagnosis. Surgery caused additional visual symptoms in
16%, whereas RT was associated with new visual deficits in
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on 684 patients, who were surgically treated for pituitary
adenomas, and, too, found visual dysfunction to be the pre-
dominant symptom leading to hospitalization in 39 to 62%
of all patients. Even though, in this cohort only few patients
suffered from additional postoperative visual dysfunction,
17.5% of all patients required reoperation, 10% suffered
from surgical complications and 1.6% died perioperatively
[4]. This emphasizes that despite being routinely per-
formed, surgery for pituitary tumors remains a perilous op-
erative intervention.
No secondary cancer was observed. We consider this
finding to be of great importance, since physicians may
be hesitant to conduct RT for benign neoplasms in crit-
ical locations. One main concern against RT for benign
lesions is the risk for long-term secondary malignancies,
especially when treating younger patients. However, only
few data is available supporting this concern. Isobe et al.
described one out of 75 patients to suffer from suprasel-
lar germinoma 45 months after RT [1]. Our work contri-
butes new insight into this question since follow-up
times are fairly long, confirming that secondary malig-
nancies are no primary concern in the treatment of pitu-
itary adenoma patients.
Pituitary dysfunction may cause severe medical condi-
tions such as dysregulation of blood pressure or glucose
metabolism, and is commonly associated with significantly
reduced QOL, e.g. related to infertiliy or corticoid-
associated stress adjustment disorders. Only 5% of all
patients who answered the questionnaire reported reduced
QOL related to RT, which supports data previously
published by van Beek et al., who found no significant dif-
ference of QOL or cognition in patients undergoing post-
operative irradiation vs. those who underwent surgery
alone [22]. Following neurosurgical transsphenoidal resec-
tion, two of three patients developed a new pituitary
deficit requiring pharmacological replacement. New pituit-
ary deficits following RT were diagnosed in 11% of our
patients, but all of these patients had undergone prior sur-
gery and were on hormone replacement therapy for post-
operative partial hypopituitarism. Reduced levels of TSH
and ACTH were the predominant side effects of RT. Prior
reports have identified the somatotropic axis to be most
vulnerable to radiation damage [9]. However, since there
was no routine monitoring of GH levels and since deficits
were defined by pharmacological replacement, radiogenic
damage to the somatotropic axis may be disguised by the
majority of adult patients not being treated for asymptom-
atic growth hormone deprivation. Interestingly, radiogenic
hypopituitarism was detected more frequently in patients
who underwent irradiation for recurrent tumors than in
those who were subjected to immediate postoperative RT.
This is the first report on a large cohort undergoing
both primary RT, but also treatment of recurrent tumorswith a long median follow-up of more than 8 years, in-
cluding 16 patients with a follow-up of >15 years and 9
patients who were followed for more than 20 years after
completion of RT. Weber et al. described 27 patients
undergoing either adjuvant or radical RT for pituitary
adenomas with a median follow-up of 6 years and found
local control rates above 95% at 5 years [6]. Sun et al.
reported on 33 patients, in whom local control rates of
94% were achieved at 36 months [3]. In our cohort, 10-
year-local control rates were 90.4%, therefore supporting
previously published data on high control rates in these
patients. However, at 20 years after RT, local control had
declined to 75.5%, indicating that long-term follow-up is
mandatory in pituitary adenoma patients. Local control
was not affected by patient sex and by hormone secre-
tion. Langsenlehner et al. showed inferior local control
of non-secreting adenomas [23]. This may be due to dif-
fering dose regimes with higher doses delivered to func-
tioning adenomas. Also, various authors have demonstrated
differential response of adenomas secreting different hor-
mones, with somatotropinomas predisposing for improved
response [1] and prolactinomas being associated with in-
ferior outcome [4]. In this cohort, hormone secretion did
not impact survival rates, and there was no difference in
dose delivery between functioning and non-functioning
adenoma patients (average dose: 51.4 vs. 52.2 Gy). All
patients received doses >45 Gy, which are known to ren-
der control rates >90% [21]. The role of photon RT has
been challenged, and previous authors have imputed inef-
ficiency to postoperative RT. One of the largest cohorts
supporting this hypothesis, however, had received median
doses of 44.0 Gy. These doses are known to be ineffective
in pituitary adenoma treatment [4].
Neurosurgical resection represents the standard treat-
ment in newly diagnosed pituitary adenomas. In the group,
reported here, neither extent of resection – as assessed by
either cross-sectional imaging or surgical reports – nor sur-
gery in general improved local control. This finding how-
ever is biased by selection with the majority of the patients
reported here suffering from adenoma recurrences follow-
ing surgery, not taking into account that many patients are
considered cured following resection. We found that our
patients, who represent those with a rather inferior progno-
sis due to either incomplete resection of extensive tumors
or because of relapse after surgery, developed tumor recur-
rences after median latencies of 36 months with patients re-
lapsing as late as 29 years after initial surgery. This finding
emphasizes the need of regular long term follow-up exami-
nations. This is impaired by the fact that until the mid 90s
no 3D cross sectional and contrast agent-enhanced imaging
was avaible to make residual disease visible and susceptible
to further treatment. In our cohort, the majority of patients
did not receive immediate post-operative imaging to con-
trol extent of resection.
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of incomplete resection mostly based upon the surgeons
intraoperative assessments. We observed improved local
control rates in these patients when comparing them to
those only irradiated for tumor recurrences. Though sta-
tistically not yet significant, we consider this finding to be
relevant, because physicians and patients may be hesitant
to conduct early postoperative RT for fear of supraaddi-
tional toxicity or for keeping it as a salvage treatment in
case of relapse. Knowing that local control is superior
while toxicity remains unaltered if not benefical over
patients treated for recurring tumors, we recommend that
in case of likely relapse, such as in incomplete resected or
locally advanced tumors, immediate postoperative RT can
improve tumor control without serious sequelae.
We are aware of the limitations of our study: Compar-
ing early postoperative RT with RT for recurrent RT in
terms of improved LPFS, carries the risk of selection bias
with possibly the more aggressive adenomas being
included in the later group. Also, we acknowledge that
no validated questionnaire was used to gather patient-
reported data on QOL. However, we still consider the
notion of generally improved QOL an important finding.
We conclude that RT for both functioning and non-
functioning pituitary adenomas is safe and effective. It
yields high local control rates with little neoplastic, cere-
bral, visual and endocrinological toxicity. QOL is not
lowered by RT. In cases of inoperability, radical RT
offers an effective and safe treatment modality.
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